EP0190255B1 - Erodible matrix for sustained release bioactive composition - Google Patents
Erodible matrix for sustained release bioactive composition Download PDFInfo
- Publication number
- EP0190255B1 EP0190255B1 EP85903908A EP85903908A EP0190255B1 EP 0190255 B1 EP0190255 B1 EP 0190255B1 EP 85903908 A EP85903908 A EP 85903908A EP 85903908 A EP85903908 A EP 85903908A EP 0190255 B1 EP0190255 B1 EP 0190255B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- weight
- polyethylene glycol
- composition
- erosion rate
- rate modifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2933—Coated or with bond, impregnation or core
- Y10T428/294—Coated or with bond, impregnation or core including metal or compound thereof [excluding glass, ceramic and asbestos]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/298—Physical dimension
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2989—Microcapsule with solid core [includes liposome]
Definitions
- This invention relates to sustained release compositions for bioactive compounds and more particularly to sustained release oral dosage forms incorporating a drug in an erodible matrix.
- One method for achieving this goal is to administer the drug continuously at a rate which balances its rate of metabolism and/or excretion.
- this goal can be attained by intravenously administering a drug, but outside of such an environment this method of administration is impractical in the great majority of cases. Consequently, the most common method of administering a drug is orally, in the form of tablets, capsules, and the like, which preferably have sustained release characteristics.
- the drug released therefrom is usually absorbed from the gastrointestinal tract and reaches the target organ via the blood stream.
- erodible matrices i.e., dosage forms wherein the drug is entrapped in a matrix which upon ingestion gradually decomposes in the intestinal fluid thereby releasing the drug for absorption.
- a dosage form is found in Schmitt, U. S. Patent 4,346,709, wherein the device comprises a drug dispersed in a bioerodible polymer which is a poly(orthoester) or a poly(orthocarbonate) containing an erosion rate modifier.
- the erosion rate modifiers of Schmitt are mono-and polybasic organic acids which adjust the pH at the surface of the erodible matrix to accelerate or retard the decomposition of the polymer in the gastric or intestinal environment.
- Sothmann, et al. in U. S. Patent 4,351,825, disclose a sustained release oral dosage form wherein a drug is dispersed in a matrix of a water-insoluble polymethacrylate, e.g., a copolymer of acrylic and methacrylic acid esters containing quaternary ammonium groups or a copolymer of methacrylic acid and methyl methacrylate, which has an anionic character.
- the granules of the matrix material are mixed with the active drug and an erosion rate modifier which is an ester of a long chain fatty acid with glycerine or a long chain alcohol.
- Kleber, et al. in U. S. Patent 4,333,919, disclose controlled release formulations comprised of a drug mixed with a copolymer of lactic and glycolic acids.
- the formulations may also contain adjuvants such as glyceryl distearate.
- the formulations are primarily intended for growth stimulants for ruminants. Accordingly, they are administered by filling open-ended steel cylinders with the formulations and placing the cylinders in the rumen of the animal. The filled steel cylinders remain in the rumen, and the growth stimulant is gradually released as the matrix is eroded by the rumen fluids.
- DE-A-3,217,071 describes a drug for the peroral application having an improved biological availability of active ingredients, which contains as sustained release component a fatty acid having a chain length of 10 to 15 atoms or a derivative thereof.
- a fatty acid having a chain length of 10 to 15 atoms or a derivative thereof contains as sustained release component a fatty acid having a chain length of 10 to 15 atoms or a derivative thereof.
- myristic acid, polyethylene glycol 6000, sodium bicarbonate and tartaric acid is used; the return of the release of a drug to baseline levels results in 5-6 hours.
- GB-A-967,610 discloses sustained release dosage form mixtures of a medicament with a monoester or diester of a polyethylene glycol.
- US-A-3,947,573 discloses an ophthalmic solution consisting essentially of an aqueous solution of an ethylene oxide polymer having a molecular weight of at least about 100,000 etc..
- the ophthalmic aqueous solution according to US-A-3,947,573 is not a composition, erodable by an aqueous liquid.
- DE-A-2,501,805 discloses compositions suitable for controlled release of biologically active compounds, e.g. pesticides, comprising a compound dispersed in a mixture of a polyethylene glycol and a polyvinyl acetate polymer.
- US-A-3,374,146 discloses sustained release dosage forms containing a medicament dissolved or suspended in a waxy material which can be myristic acid and may also contain a polyethylene glycol.
- a waxy material which can be myristic acid and may also contain a polyethylene glycol.
- the examples of this reference disclose mixtures of a medicament with glyceryl monostearate or with a polyethylene glycol of unspecified molecular weight.
- EP-A-0,097,507 discloses a dosage form for ruminant animals comprising a pellet of compressed nutrient or other biologically active substance coated with a thin brittle layer of a synthetic resin to control the rate of dissolution of the pellet within the rumen.
- DE-C-287,292 discloses a dosage form wherein a medicament is coated with an enteric coating to prevent dissolution of the dosage form before it has reached the small intestine.
- This reference merely discloses the conventional method of delaying dissolution of a medicament by the use of a fatty enteric coating.
- a further object is to provide an oral, sustained release dosge form incorporating an erosion rate modifier substance.
- a further object is to provide an oral, sustained release dosage form whose formulaton and/or structure can be adjusted to release its medication either in the stomach or the small intestine.
- a further object is to provide a sustained release composition containing a bioactive compound which is released by erosion of the matrix in an aqueous liquid environment.
- a further object is to provide a liquid-erodible composition wherein the rate of erosion can be adjusted by incorporation of an erosion rate modifier.
- a further object is to provide a liquid-erodible composition wherein the rate of erosion can be adjusted to vary with the pH of the surrounding aqueous liquid.
- composition erodible by an aqueous liquid containing a polyethylene glycol and an erosion rate modifier comprising:
- composition erodible by an aqueous liquid containing a polyethylene glycol and an erosion rate modifier comprising:
- the invention further relates to a composition erodible by an aqueous liquid containing a polyethylene glycol and an erosion rate modifier, comprising:
- a sustained release dosage form according to the invention comprises a matrix of the erodible composition of the invention having dissolved or dispersed therein a bioactive compound to be released over a period of time.
- composition of this invention which makes it useful in sustained release preparations of bioactive material is its erodible character. Because it is the surface of an erodible composition which dissolves or decomposes into the surrounding medium and the eroding liquid does not substantially penetrate its structure, it is possible to achieve superior control of the dissolution rate of the solid composition, so that it may be used in a variety of applications.
- the erodible matrix of this invention is especially suitable for incorporating a drug to be administered over a period of time via the intestinal absorption route. It is formed from a composition comprising solid polyethylene glycol and an amphiphilic erosion rate modifier, and the kinetics of its drug release are determined by the properties of the matrix and the shape of the dosage form. Accordingly, the rate of release can be controlled by varying the size and shape of the dosage form as well as the proportion and type of the erosion rate modifier.
- the solid polythylene glycol component of the erodible matrix of this invention may be any polyethylene glycol (PEG) having a molecular weight from about 1000 to about 20000. All of the polyethylene glycols in this range are solid materials which are soluble in water and which will slowly dissolve when in contact with an aqueous medium. Mixtures of polyethylene glycols of different molecular weights may also be used.
- a preferred PEG is that having a molecular weight of about 8000.
- the PEG component of the erodible matrix may be present in amounts ranging from about 5 % to about 95 % by weight of the erodible matrix, preferably from 40 % to 80 % by weight.
- the erosion rate modifier is an insoluble amphiphile, that is, a material whose molecule possesses a hydrophilic portion and a lipophilic portion, usually located at opposite ends of a relatively elongated molecule.
- the presence of lipophilic portions in the erosion rate modifier slows down the rate at which the matrix is eroded when in contact with an aqueous liquid environment. Therefore, the rate of erosion can be slightly retarded by incorporating relatively small amounts of erosion rate modifier and greatly retarded by incorporating relatively large amounts of erosion rate modifier.
- the erosion rate modifier can also be chosen to vary the rate of erosion under varying conditions of pH.
- the erosion rate modifier is a long chain fatty acid such as myristic acid
- the erosion rate of the matrix will be relatively slow in acid media wherein the carboxyl group of the myristic acid is not ionized and the amphiphilic molecule is accordingly relatively hydrophobic.
- the carboxyl group is ionized, and therefore hydrophilic, which makes the erosion rate considerably faster.
- a dosage form made from such a formulation releases relatively little of a drug in the acidic environment of the stomach, but subsequently more freely releases the drug in the basic environment of the small intestine.
- erosion rate modifiers having basic groups which are ionized under acidic conditions can be incorporated in the matrix composition.
- the erosion rate modifier can also be chosen to compensate for the effects of charged forms of the bioactive compound on the erosion rate.
- the bioactive compound e. g., a drug
- the ionic character of the drug can affect the rate of erosion at various pH's of the eroding environment.
- an acidic erosion rate modifier e. g., a long chain fatty acid such as myristic acid
- the acid will remain un-ionized in the acidic environment of the stomach and thereby act to retard the erosion rate and counterbalance the effect of the basic drug.
- erosion rate modifiers devoid of ionizable hydrophilic groups, such as long chain aliphatic alcohols, results in an erodible matrix whose rate of erosion is not greatly affected by the pH of the environment.
- the erosion rate modifier may be present in the erodible compositions of this invention in amounts of about 95 % to about 5% by weight, preferably from about 60 % to about 20 % by weight.
- Suitable erosion rate modifiers include C12-C20 fatty acids, such as lauric acid, myristic, acid, palmitic acid, stearic acid, and arachidic acid; C12-C20 alcohols, such as lauryl alcohol, myristyl alcohol, palmityl alcohol, stearyl alcohol and arachidyl alcohol, amphiphilic esters of fatty acids with glycerol, particularly monoesters of C12-C20 fatty acids such as glyceryl monopalmitate, C12-C20 amines such as lauryl amine, myristyl amine, palmityl amine, stearyl amine and arachidyl amine, and amides of C12-C20 fatty acids.
- C12-C20 fatty acids such as lauric acid, myristic, acid, palmitic acid, stearic acid, and arachidic acid
- C12-C20 alcohols such as lauryl alcohol, myristyl alcohol, palmityl alcohol,
- the rate of drug release can be controlled by varying the shape of the dosage form or by coating the surface of the dosage form.
- an erodible dosage form of the invention may have a cylindrical shape wherein the height of the cylinder is much greater than the diameter, so that most of the area of the cylinder exposed to the erosive action of the aqueous liquid medium is constituted by the curved peripheral surface of the cylinder.
- the peripheral surface of the cylinder will be eroded.
- the diameter of the cylinder decreases though its erosion, the area of the peripheral surface exposed to the erosive action of the aqueous liquid environment decreases proportionally.
- the dosage form will erode at a rate which will provide approximately first order drug release kinetics. If a cylindrical dosage form has a relatively small height compared with its diameter, so that most of the exposed area is provided by the bases of the cylinder, the eroding surface area of the dosage form will not change greatly as erosion proceeds. In this case the rate of drug release will be substantially constant, i. e., the drug release kinetics will be approximately zero order.
- the surface of the dosage form can be partially coated with a liquid-impervious coating so that only certain surfaces of the dosage form are exposed to the erosive action of the medium.
- This method also allows for adjusting the kinetics of drug release. For example, if a cylindrical dosage form is coated on its curved peripheral surface so that only the ends of the cylinder are exposed to the erosive action of the medium, the area of the dosage form exposed to erosive action will not change with time. In this embodiment, therefore, the drug will be released at a constant rate, i. e., the release kinetics will be approximately zero order.
- the coating be non-self-supporting. If the coating is self-supporting it will extend beyond the ends of the cylindrical portion remaining after a portion of the dosage form has been eroded. This extension will interfere with the access of the eroding aqueous liquid medium to the ends of the cylinder and will, accordingly, affect the kinetics. Therefore, the preferred coating for this type of dosage form is a very thin friable material which is not self-supporting.
- any portion extending beyond the end of the cylinder after the immediately underlying matrix has been eroded will be broken off as the dosage form is subjected to agitation in the gastrointestinal tract, thus keeping the uncoated ends of the cylinder fully exposed to the erosive action of the medium.
- coating material in the form of a melt which solidifies by cooling on the surface of the dosage form.
- Preferred coating materials are long chain fatty acids having 12 to 20 carbon atoms. Such acids include lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid.
- the thickness of the coating will typically be from about 0.02 mm to about 0.5 mm.
- Additional ingredients can be incorporated into the erodible composition of this invention to modify and/or control the properties of the composition.
- a modified polyethylene glycol wherein the OH groups at one or both ends are esterified with long chain fatty acids may be added to the mixture.
- Suitable long chain fatty acids are aliphatic fatty acids having from about 12 to about 20 carbon atoms such as those disclosed above.
- Preferred polyethylene glycols to be used in preparing the esterified PEG compatibility enhancers are those having a molecular weight from about 200 to 10000, preferably from about 200 to about 2000, PEG 400 and PEG 600 are particularly preferred materials for preparing the esterified PEG's.
- the esterified PEG's may be the monoesters and prefereably the lauric or stearic ester. More preferred esters are the diesters, particularly the dilauroyl and distearoyl esters.
- These modified polyethylene glycols are prepared by conventional esterification procedures well known to those skilled in the art, such as reacting the polyethylene glycol with the acid chloride of the chosen acid.
- the modified polyethylene glycol may be incorporated into the compositions of this invention in any effective amounts, such as in an amount up to about 10 % by weight, preferably from about 0.1 % to about 10 % by weight, and particularly about 2 % by weight.
- Starch may also be added to the erodible mixture of this invention as a disintegrant in order to adjust the erosion rate.
- the starch tends to enhance the erodible characteristics of the composition by causing the solid material to dissolve from the surface without penetration of the aqueous liquid into the interior of the solid form.
- Any type of starch may be used, particularly a pharmaceutically acceptable and readily available form of starch, such as cornstarch.
- Starch may be present in amounts of from about 5 % by weight to about 60 % by weight, preferably from about 10 % by weight to about 50 % by weight, and more preferably from about 20 % by weight to about 40 % by weight.
- Molding adjuvants may also be added to the compositions of this invention. It has been found that the addition of a polyethylene oxide (PEO) having a molecular weight (MW) from about 100,000 to about 5 x 106 has beneficial effects on the viscosity and plasticity of the composition. This provides for easier mold filling and release of molded forms from the molds, especially when molded dosage forms of this invention are prepared by injection molding.
- the PEO may be present in an effective amount up to about 2 % by weight, preferably from about 0.05 % by weight to about 1 % by weight, and most preferably about 0.1 % by weight. It will be appreciated by those skilled in the art that injection molding of compositions containing a relatively large number of ingredients, such as the compositions of this invention, is not common. Hence, some experimentation may be required to determine the exact amount of molding adjuvant needed for a given composition.
- the erodible matrix of this invention is useful wherever controlled release of a material into an aqueous liquid environment is desired.
- Such an erodible material may be used, for example, without an incorporated drug as a coating for a substance designed for a delayed dissolution after immersion in an aqueous liquid. It may serve a similar function when employed as a plug for a container intended to release a material on a delayed-action basis when immersed or contacted with an aqueous liquid.
- the erodible composition of this invention may also contain an ecological agent dispersed therein in order to provide for gradual release of the ecological agent into into an aqueous liquid environment.
- An ecological agent is defined for purposes of this invention as a non-pharmaceutical substance which has a biological effect on plants or animals in the environment.
- An ecological agent may be a pesticide, such as an insecticide or herbicide, a fertilizer, a pheromone, a plant growth hormone, or the like. When dosage forms made from compositions containing such bioactive ingredients contact an aqueous liquid environment the bioactive materials are gradually released into the environment.
- compositions of this invention are useful for releasing such ecological agents into bodies of water or into a land environment where they may release their active agents by contact with rain or standing water, so as to maintain an effective concentration of the agent in the environment for a relatively long period of time.
- the erodible matrix of this invention as a carrier for sustained release pharmaceuticals administered orally to individuals in need of a relatively constant concentration of medication.
- the drugs may be locally or systemically acting drugs, and may be selected from among any group wherein a steady concentration of the drug in the organism is desired.
- the drug may be selected from among analgesic, anorexic, antiarthritic, antibacterial, antibiotic, anticonvulsant, anti-depressant, antidiabetic, anti-fungal, antihistaminic, anti-hypertensive, anti-inflammatory, anti-neoplastic, antiparkinsonism, anti-pyretic, anticholinergic, anti-inflammatory, anesthetic, antimicrobial, antiviral, anti-ulcer, bronchodilator, cardiovascular, contraceptive, central nervous system affecting, inotropic, vasodilator, vasoconstrictor, decongestant, diuretic, hypoglycemic, hormone, hypnotic, hematinic, electrolyte supplement, germicidal, muscle relaxant, parasympathetolytic, parasympathetomimetic, tranquilizer, ophthalmic, psycho-stimulant, vitamin, and the like drugs.
- the drugs can be administered in the form of the parent compound as well as in the form of
- Preferred drugs for use in the dosage forms prepared according to the invention include clonidine, theophylline, quinidine, dipyridamole, hydrochlorothiazide, scopolamine, indomethacin, furosemide, potassium chloride and the like.
- the drug to be released from the dosage form of the invention may be incorporated into the erodible matrix simply by dissolving it in the molten matrix or mixing it therewith.
- the proportions of drug and erodible matrix in the dosage forms of this invention may vary within wide limits. Because some drugs are effective in very small doses and others require relatively large doses for effect, the proportions will vary depending on the amount of drug which must be incorporated into the unit dosage form. Accordingly, the drug may be constitute in an effective amount up to about 70 % by weight of the composition. More preferably the drug will constitute from about 0.1 % to about 50 % by weight of the composition, with the balance being the erodible matrix.
- the unit dosage forms of the invention can be prepared by conventional procedures such as compression molding, tableting, extrusion, and injection molding. It is preferred that the dosage forms of the invention be non-porous in order that the erosion will proceed from the surface of the dosage form. Such non-porous dosage forms are best prepared by solidification of a molten form of the composition containing all ingredients of the composition, and injection molding is especially useful for that purpose. Indeed, the dosage forms of the invention are especially adapted to production by injection molding because the erodible matrix composition of the invention has a relatively low melting temperature, and hence the injection molding can be carried out at a temperature which is not detrimental to the drug contained in the dosage form.
- the preferred dosage forms of the invention have a cylindrical shape with a diameter of about 3 mm to about 8 mm, and preferably about 5 mm.
- the length of the cylindrical dosage form is typically about 5 mm to about 20 mm, and is preferably about 10 mm.
- the preferred dosage forms may be coated on their peripheral cylindrical surfaces with a liquid-impervious non-self-supporting coating as discussed above.
- sustained release compositions of this invention are prepared by the following general procedure.
- a premeasured amount of a polyethylene glycol is melted in a vessel, e. g., a kettle provided with a steam jacket or a heating mantle and equipped with a stirring mechanism.
- a temperature of about 85°C is sufficient to melt any of the polyethylene glycols.
- the premeasured amount of the insoluble amphiphile is then added either as a molten liquid or as a solid. It is preferred to melt the insoluble amphiphile and add it slowly to the stirred molten PEG.
- the long chain fatty amphiphiles useful in the compositions of this invention are generally molten at the temperature of the molten PEG and can be readily mixed with the PEG.
- the bioactive agent, drug or the like is then added and dissolved in the molten mixture.
- ingredients such as disintegrants (e. g., starch), molding adjuvants (e. g., polyethylene oxide), and the like are then added and the mixture is thoroughly blended. Dosage forms may then be formed directly from the molten mixture by the procedures outlined above.
- disintegrants e. g., starch
- molding adjuvants e. g., polyethylene oxide
- This example illustrates the preparation of dosage forms of the invention containing polyethylene glycols of various molecular weights.
- compositions were prepared having the following compositions: A. PEG-1000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % B. PEG-4000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % C. PEG-8000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % D. PEG-20,000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 %
- Cylindrical dosage forms were molded from the compositions A - D by pouring the molten compositions into open-ended plastic molds made of polyethylene having a diameter of about 6 mm and allowing the melt to cool to room temperature. The solidified composition was then extruded from the molds and cut into lengths to prepare cylindrical dosage forms. In this way dosage forms having a diameter of about 6 mm and a length of about 14 mm and weighing about 0.44 g each were prepared.
- SIF Simulated intestinal fluid
- Each of the cylindrical dosage forms was placed in 80 ml of SIF at 37 °C and subjected to gentle agitation. The amount of drug released was monitored by measuring the optical density of the aqueous medium at an absorption peak of indomethacin at intervals using an ultraviolet spectrophotometer. Each of the dosage forms was found to release the drug gradually over a period of several hours.
- Cylindrical dosage forms of the same size and shape as above were prepared from each of the compositions A - D, but these cylinders were coated on their cylindrical surfaces with myristic acid by dipping the cylinders in molten myristic acid, withdrawing the cylinders and allowing the myristic acid coating to cool and harden, and then scraping the coating from the ends of the cylinders.
- These dosage forms were tested in SIF by the same procedure as the uncoated dosage forms. They also were found to release the drug over a period of several hours with the drug release occurring at an approximately constant rate.
- This example illustrates variation of the fatty acid erosion rate modifier.
- Example 1 Several dosage forms were prepared by the procedure of Example 1 having the following compositions: A. PEG-8000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % B. PEG-8000 37.5 % Palmitic acid 15 % Starch 22.5 % Indomethacin 25 % C. PEG-8000 37.5 % Stearic acid 15 % Starch 22.5 % Indomethacin 25 %
- the dosage forms were tested by the procedure of Example 1 and were found to release the drug over a period of several hours at a relatively constant rate.
- This example illustrates another composition of the invention incorporating additional ingredients.
- a sustained release composition was prepared by the general procedure disclosed above having the following composition: PEG-8000 27 % Palmitic acid 13 % PEG 400 monostearate 10 % PEO (MW 5 x 106) 0.1 % Cornstarch 49.8 % Clonidine HCl 0.1 %
- the molten mixture was poured onto a surface and allowed to cool and solidify.
- the solid material was then granulated and fed into an injection molding machine to form dosage forms according to the invention.
- This example illustrates preparation of PEG esters.
- PEG-8000 was melted in a vessel equipped with a stirrer and heated to 100°C. An amount of myristyl chloride equivalent to one half of the terminal hydroxyl groups of the PEG was melted and added dropwise to the molten PEG with continuous stirring. Chloroform was added to the mixture and the solution was filtered through filter paper (Whatman No. 4) and allowed to stand overnight to evaporate the solvent. The remaining solvent was evaporated the next day by heating at 60°C. The material so obtained was a hard waxy solid having a melting point of about 60°C.
- This example illustrates the preparation of dosage forms of the invention using various drugs.
- Sustained release compositions were prepared by the general procedure disclosed above having the following compositions: A. PEG (MW 3,350) 37 % Stearyl alcohol 15 % Theophylline 50 % B. PEG 8000 30 % Myristic acid 20 % PEG 400 monostearate 10 % PEO (MW 5 x 106) 0.1 % Corn starch 24.9 % Dipyridamole 15 % C. PEG-8000 2.8 g Myristic acid 1.2 g Starch 1.8 g Hydrochlorothiazide 50 mg D. PEG-8000 1.5 g Myristic acid 0.6 g Starch 0.9 g Furosemide 1.0 g E.
- This example illustrates a dosage form of this invention incorporating a pesticide.
- a composition of the invention was prepared by the procedure of Example 1 having the following composition: PEG-8000 37.5 % Myristic acid 15.0 % Starch 22.5 % Carbofuran 25.0 %
- Cylindrical dosage forms (uncoated) were prepared by the procedure of Example 1. These dosage forms were found to erode over a period of about one day in an aqueous environment.
- This example illustrates the preparation of a coated dosage form of the invention.
- a composition was prepared by the procedure of Example 1 having the following composition: PEG-3350 27 % Myristic acid 13 % PEG-400 distearate 2 % Potato starch 13 % Quinidine ⁇ 2 H2SO4 45 %
- the extruded cylinder was then cut into dosage forms having a length of about 10 mm and dosage forms were tested as in Example 1 and found to release the drug over a period of time.
Abstract
Description
- This invention relates to sustained release compositions for bioactive compounds and more particularly to sustained release oral dosage forms incorporating a drug in an erodible matrix.
- In chemotherapy of diseases it is frequently desirable to maintain the concentration of the therapeutic drug at a relatively constant level in the blood or organ being treated. One method for achieving this goal is to administer the drug continuously at a rate which balances its rate of metabolism and/or excretion. In a hospital environment this goal can be attained by intravenously administering a drug, but outside of such an environment this method of administration is impractical in the great majority of cases. Consequently, the most common method of administering a drug is orally, in the form of tablets, capsules, and the like, which preferably have sustained release characteristics. The drug released therefrom is usually absorbed from the gastrointestinal tract and reaches the target organ via the blood stream.
- Among the various types of sustained release dosage forms which have been developed are erodible matrices, i.e., dosage forms wherein the drug is entrapped in a matrix which upon ingestion gradually decomposes in the intestinal fluid thereby releasing the drug for absorption. An example of such a dosage form is found in Schmitt, U. S. Patent 4,346,709, wherein the device comprises a drug dispersed in a bioerodible polymer which is a poly(orthoester) or a poly(orthocarbonate) containing an erosion rate modifier. The erosion rate modifiers of Schmitt are mono-and polybasic organic acids which adjust the pH at the surface of the erodible matrix to accelerate or retard the decomposition of the polymer in the gastric or intestinal environment.
- In a further example, Sothmann, et al., in U. S. Patent 4,351,825, disclose a sustained release oral dosage form wherein a drug is dispersed in a matrix of a water-insoluble polymethacrylate, e.g., a copolymer of acrylic and methacrylic acid esters containing quaternary ammonium groups or a copolymer of methacrylic acid and methyl methacrylate, which has an anionic character. The granules of the matrix material are mixed with the active drug and an erosion rate modifier which is an ester of a long chain fatty acid with glycerine or a long chain alcohol.
- Additionally, Kleber, et al., in U. S. Patent 4,333,919, disclose controlled release formulations comprised of a drug mixed with a copolymer of lactic and glycolic acids. The formulations may also contain adjuvants such as glyceryl distearate. The formulations are primarily intended for growth stimulants for ruminants. Accordingly, they are administered by filling open-ended steel cylinders with the formulations and placing the cylinders in the rumen of the animal. The filled steel cylinders remain in the rumen, and the growth stimulant is gradually released as the matrix is eroded by the rumen fluids.
- DE-A-3,217,071 describes a drug for the peroral application having an improved biological availability of active ingredients, which contains as sustained release component a fatty acid having a chain length of 10 to 15 atoms or a derivative thereof. According to the only example the combination of myristic acid, polyethylene glycol 6000, sodium bicarbonate and tartaric acid is used; the return of the release of a drug to baseline levels results in 5-6 hours.
- GB-A-967,610 discloses sustained release dosage form mixtures of a medicament with a monoester or diester of a polyethylene glycol.
- US-A-3,947,573 discloses an ophthalmic solution consisting essentially of an aqueous solution of an ethylene oxide polymer having a molecular weight of at least about 100,000 etc.. The ophthalmic aqueous solution according to US-A-3,947,573 is not a composition, erodable by an aqueous liquid.
- DE-A-2,501,805 discloses compositions suitable for controlled release of biologically active compounds, e.g. pesticides, comprising a compound dispersed in a mixture of a polyethylene glycol and a polyvinyl acetate polymer.
- US-A-3,374,146 discloses sustained release dosage forms containing a medicament dissolved or suspended in a waxy material which can be myristic acid and may also contain a polyethylene glycol. The examples of this reference disclose mixtures of a medicament with glyceryl monostearate or with a polyethylene glycol of unspecified molecular weight.
- EP-A-0,097,507 discloses a dosage form for ruminant animals comprising a pellet of compressed nutrient or other biologically active substance coated with a thin brittle layer of a synthetic resin to control the rate of dissolution of the pellet within the rumen.
- DE-C-287,292 discloses a dosage form wherein a medicament is coated with an enteric coating to prevent dissolution of the dosage form before it has reached the small intestine. This reference merely discloses the conventional method of delaying dissolution of a medicament by the use of a fatty enteric coating.
- It seems evident from these disclosures, that the erodible formulations of the prior art have generally required specially prepared polymers, and that the rate of erosion of such polymers cannot always be adjusted to provide for preferential release of the drug in a particular portion of the gastrointestinal tract, e.g., in the stomach or small intestine.
- Therefore, a need has continued to exist for an erodible matrix, prepared from readily available materials which are suitable for sustained release pharmaceutical formulations, wherein the rate of erosion can be substantially controlled.
- Accordingly, it is an object of this invention to provide an oral, sustained release dosage form.
- A further object is to provide an oral, sustained release dosge form incorporating an erosion rate modifier substance.
- A further object is to provide an oral, sustained release dosage form whose formulaton and/or structure can be adjusted to release its medication either in the stomach or the small intestine.
- A further object is to provide a sustained release composition containing a bioactive compound which is released by erosion of the matrix in an aqueous liquid environment.
- A further object is to provide a liquid-erodible composition wherein the rate of erosion can be adjusted by incorporation of an erosion rate modifier.
- A further object is to provide a liquid-erodible composition wherein the rate of erosion can be adjusted to vary with the pH of the surrounding aqueous liquid.
- Additional objects will become apparent from the description of the invention which follows.
- The objects of the invention are achieved by a composition erodible by an aqueous liquid containing a polyethylene glycol and an erosion rate modifier, comprising:
- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;
- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqueous liquid, and 0.1 to 10% by weight of a polyethylene glycol having a molecular weight from about 200 to about 10,000 and having at one or both ends OH groups esterified with a c₁₂ - c₂₀ aliphatic fatty acid which increases the compatibility of the polyethylene glycol and the erosion rate modifier;
- The objects of the invention are further achieved by a composition erodible by an aqueous liquid containing a polyethylene glycol and an erosion rate modifier, comprising:
- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;
- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqueous liquid; and
- 5 to 60% by weight of starch as a disintegrant;
- The invention further relates to a composition erodible by an aqueous liquid containing a polyethylene glycol and an erosion rate modifier, comprising:
- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;
- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqueous liquid;
- 5 to 60% by weight of starch as a disintegrant; and
- 0.1 to 10% by weight of a polyethylene glycol having a molecular weight from about 200 to about 10,000 and having at one or both ends OH groups esterified with a C₁₂ - C₂₀ aliphatic fatty acid which increases the compatibility of the polyethyelene glycol and the erosion rate modifier;
- A sustained release dosage form according to the invention comprises a matrix of the erodible composition of the invention having dissolved or dispersed therein a bioactive compound to be released over a period of time.
- The property of the composition of this invention which makes it useful in sustained release preparations of bioactive material is its erodible character. Because it is the surface of an erodible composition which dissolves or decomposes into the surrounding medium and the eroding liquid does not substantially penetrate its structure, it is possible to achieve superior control of the dissolution rate of the solid composition, so that it may be used in a variety of applications.
- The erodible matrix of this invention is especially suitable for incorporating a drug to be administered over a period of time via the intestinal absorption route. It is formed from a composition comprising solid polyethylene glycol and an amphiphilic erosion rate modifier, and the kinetics of its drug release are determined by the properties of the matrix and the shape of the dosage form. Accordingly, the rate of release can be controlled by varying the size and shape of the dosage form as well as the proportion and type of the erosion rate modifier.
- The solid polythylene glycol component of the erodible matrix of this invention may be any polyethylene glycol (PEG) having a molecular weight from about 1000 to about 20000. All of the polyethylene glycols in this range are solid materials which are soluble in water and which will slowly dissolve when in contact with an aqueous medium. Mixtures of polyethylene glycols of different molecular weights may also be used. A preferred PEG is that having a molecular weight of about 8000. The PEG component of the erodible matrix may be present in amounts ranging from about 5 % to about 95 % by weight of the erodible matrix, preferably from 40 % to 80 % by weight.
- The erosion rate modifier is an insoluble amphiphile, that is, a material whose molecule possesses a hydrophilic portion and a lipophilic portion, usually located at opposite ends of a relatively elongated molecule. The presence of lipophilic portions in the erosion rate modifier slows down the rate at which the matrix is eroded when in contact with an aqueous liquid environment. Therefore, the rate of erosion can be slightly retarded by incorporating relatively small amounts of erosion rate modifier and greatly retarded by incorporating relatively large amounts of erosion rate modifier.
- The erosion rate modifier can also be chosen to vary the rate of erosion under varying conditions of pH. For example, if the erosion rate modifier is a long chain fatty acid such as myristic acid, the erosion rate of the matrix will be relatively slow in acid media wherein the carboxyl group of the myristic acid is not ionized and the amphiphilic molecule is accordingly relatively hydrophobic. On the other hand, under basic conditions the carboxyl group is ionized, and therefore hydrophilic, which makes the erosion rate considerably faster. Evidently, a dosage form made from such a formulation releases relatively little of a drug in the acidic environment of the stomach, but subsequently more freely releases the drug in the basic environment of the small intestine. In the event that erosion of the matrix in the stomach is desired, then erosion rate modifiers having basic groups which are ionized under acidic conditions can be incorporated in the matrix composition.
- The erosion rate modifier can also be chosen to compensate for the effects of charged forms of the bioactive compound on the erosion rate. When the bioactive compound, e. g., a drug, is present in the matrix of the invention in amounts greater than about 2-3 % by weight of the total composition, the ionic character of the drug can affect the rate of erosion at various pH's of the eroding environment. For, example if the erodible matrix contains a basic drug, which will assume a positive charge in the acidic environment of the stomach, thereby increasing the erosion rate, an acidic erosion rate modifier, e. g., a long chain fatty acid such as myristic acid, may be used as an erosion rate modifier. The acid will remain un-ionized in the acidic environment of the stomach and thereby act to retard the erosion rate and counterbalance the effect of the basic drug.
- Use of erosion rate modifiers devoid of ionizable hydrophilic groups, such as long chain aliphatic alcohols, results in an erodible matrix whose rate of erosion is not greatly affected by the pH of the environment.
- The erosion rate modifier may be present in the erodible compositions of this invention in amounts of about 95 % to about 5% by weight, preferably from about 60 % to about 20 % by weight.
- Suitable erosion rate modifiers include C₁₂-C₂₀ fatty acids, such as lauric acid, myristic, acid, palmitic acid, stearic acid, and arachidic acid; C₁₂-C₂₀ alcohols, such as lauryl alcohol, myristyl alcohol, palmityl alcohol, stearyl alcohol and arachidyl alcohol, amphiphilic esters of fatty acids with glycerol, particularly monoesters of C₁₂-C₂₀ fatty acids such as glyceryl monopalmitate, C₁₂-C₂₀ amines such as lauryl amine, myristyl amine, palmityl amine, stearyl amine and arachidyl amine, and amides of C₁₂-C₂₀ fatty acids.
- In various dosage forms embodiments of this invention, the rate of drug release can be controlled by varying the shape of the dosage form or by coating the surface of the dosage form. For example, an erodible dosage form of the invention may have a cylindrical shape wherein the height of the cylinder is much greater than the diameter, so that most of the area of the cylinder exposed to the erosive action of the aqueous liquid medium is constituted by the curved peripheral surface of the cylinder. When such a cylinder is immersed in a liquid medium the peripheral surface of the cylinder will be eroded. As the diameter of the cylinder decreases though its erosion, the area of the peripheral surface exposed to the erosive action of the aqueous liquid environment decreases proportionally. Therefore, the dosage form will erode at a rate which will provide approximately first order drug release kinetics. If a cylindrical dosage form has a relatively small height compared with its diameter, so that most of the exposed area is provided by the bases of the cylinder, the eroding surface area of the dosage form will not change greatly as erosion proceeds. In this case the rate of drug release will be substantially constant, i. e., the drug release kinetics will be approximately zero order.
- In another embodiment, the surface of the dosage form can be partially coated with a liquid-impervious coating so that only certain surfaces of the dosage form are exposed to the erosive action of the medium. This method also allows for adjusting the kinetics of drug release. For example, if a cylindrical dosage form is coated on its curved peripheral surface so that only the ends of the cylinder are exposed to the erosive action of the medium, the area of the dosage form exposed to erosive action will not change with time. In this embodiment, therefore, the drug will be released at a constant rate, i. e., the release kinetics will be approximately zero order.
- In order to assure that the rate of drug release will actually remain substantially constant for this coated cylindrical dosage form, it is necessary that the coating be non-self-supporting. If the coating is self-supporting it will extend beyond the ends of the cylindrical portion remaining after a portion of the dosage form has been eroded. This extension will interfere with the access of the eroding aqueous liquid medium to the ends of the cylinder and will, accordingly, affect the kinetics. Therefore, the preferred coating for this type of dosage form is a very thin friable material which is not self-supporting. With such a coating, any portion extending beyond the end of the cylinder after the immediately underlying matrix has been eroded will be broken off as the dosage form is subjected to agitation in the gastrointestinal tract, thus keeping the uncoated ends of the cylinder fully exposed to the erosive action of the medium.
- In most cases it will be convenient to apply the coating material in the form of a melt which solidifies by cooling on the surface of the dosage form. Preferred coating materials are long chain fatty acids having 12 to 20 carbon atoms. Such acids include lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid. The thickness of the coating will typically be from about 0.02 mm to about 0.5 mm.
- Additional ingredients can be incorporated into the erodible composition of this invention to modify and/or control the properties of the composition. For example, in order to improve the compatibility between the polyethylene glycol and the erosion rate modifier and prevent phase separation when the molten composition is cooled, a modified polyethylene glycol wherein the OH groups at one or both ends are esterified with long chain fatty acids may be added to the mixture. Suitable long chain fatty acids are aliphatic fatty acids having from about 12 to about 20 carbon atoms such as those disclosed above. Preferred polyethylene glycols to be used in preparing the esterified PEG compatibility enhancers are those having a molecular weight from about 200 to 10000, preferably from about 200 to about 2000, PEG 400 and PEG 600 are particularly preferred materials for preparing the esterified PEG's. For example, the esterified PEG's may be the monoesters and prefereably the lauric or stearic ester. More preferred esters are the diesters, particularly the dilauroyl and distearoyl esters. These modified polyethylene glycols are prepared by conventional esterification procedures well known to those skilled in the art, such as reacting the polyethylene glycol with the acid chloride of the chosen acid. The modified polyethylene glycol may be incorporated into the compositions of this invention in any effective amounts, such as in an amount up to about 10 % by weight, preferably from about 0.1 % to about 10 % by weight, and particularly about 2 % by weight.
- Starch may also be added to the erodible mixture of this invention as a disintegrant in order to adjust the erosion rate. The starch tends to enhance the erodible characteristics of the composition by causing the solid material to dissolve from the surface without penetration of the aqueous liquid into the interior of the solid form. Any type of starch may be used, particularly a pharmaceutically acceptable and readily available form of starch, such as cornstarch. Starch may be present in amounts of from about 5 % by weight to about 60 % by weight, preferably from about 10 % by weight to about 50 % by weight, and more preferably from about 20 % by weight to about 40 % by weight.
- Molding adjuvants may also be added to the compositions of this invention. It has been found that the addition of a polyethylene oxide (PEO) having a molecular weight (MW) from about 100,000 to about 5 x 10⁶ has beneficial effects on the viscosity and plasticity of the composition. This provides for easier mold filling and release of molded forms from the molds, especially when molded dosage forms of this invention are prepared by injection molding. The PEO may be present in an effective amount up to about 2 % by weight, preferably from about 0.05 % by weight to about 1 % by weight, and most preferably about 0.1 % by weight. It will be appreciated by those skilled in the art that injection molding of compositions containing a relatively large number of ingredients, such as the compositions of this invention, is not common. Hence, some experimentation may be required to determine the exact amount of molding adjuvant needed for a given composition.
- The erodible matrix of this invention is useful wherever controlled release of a material into an aqueous liquid environment is desired. Such an erodible material may be used, for example, without an incorporated drug as a coating for a substance designed for a delayed dissolution after immersion in an aqueous liquid. It may serve a similar function when employed as a plug for a container intended to release a material on a delayed-action basis when immersed or contacted with an aqueous liquid.
- The erodible composition of this invention may also contain an ecological agent dispersed therein in order to provide for gradual release of the ecological agent into into an aqueous liquid environment. An ecological agent is defined for purposes of this invention as a non-pharmaceutical substance which has a biological effect on plants or animals in the environment. An ecological agent may be a pesticide, such as an insecticide or herbicide, a fertilizer, a pheromone, a plant growth hormone, or the like. When dosage forms made from compositions containing such bioactive ingredients contact an aqueous liquid environment the bioactive materials are gradually released into the environment. Accordingly, the compositions of this invention are useful for releasing such ecological agents into bodies of water or into a land environment where they may release their active agents by contact with rain or standing water, so as to maintain an effective concentration of the agent in the environment for a relatively long period of time.
- It is preferred to use the erodible matrix of this invention as a carrier for sustained release pharmaceuticals administered orally to individuals in need of a relatively constant concentration of medication. The drugs may be locally or systemically acting drugs, and may be selected from among any group wherein a steady concentration of the drug in the organism is desired. Accordingly, the drug may be selected from among analgesic, anorexic, antiarthritic, antibacterial, antibiotic, anticonvulsant, anti-depressant, antidiabetic, anti-fungal, antihistaminic, anti-hypertensive, anti-inflammatory, anti-neoplastic, antiparkinsonism, anti-pyretic, anticholinergic, anti-inflammatory, anesthetic, antimicrobial, antiviral, anti-ulcer, bronchodilator, cardiovascular, contraceptive, central nervous system affecting, inotropic, vasodilator, vasoconstrictor, decongestant, diuretic, hypoglycemic, hormone, hypnotic, hematinic, electrolyte supplement, germicidal, muscle relaxant, parasympathetolytic, parasympathetomimetic, tranquilizer, ophthalmic, psycho-stimulant, vitamin, and the like drugs. The drugs can be administered in the form of the parent compound as well as in the form of pharmaceutically acceptable salts, and precursors.
- Preferred drugs for use in the dosage forms prepared according to the invention include clonidine, theophylline, quinidine, dipyridamole, hydrochlorothiazide, scopolamine, indomethacin, furosemide, potassium chloride and the like.
- The drug to be released from the dosage form of the invention may be incorporated into the erodible matrix simply by dissolving it in the molten matrix or mixing it therewith.
- The proportions of drug and erodible matrix in the dosage forms of this invention may vary within wide limits. Because some drugs are effective in very small doses and others require relatively large doses for effect, the proportions will vary depending on the amount of drug which must be incorporated into the unit dosage form. Accordingly, the drug may be constitute in an effective amount up to about 70 % by weight of the composition. More preferably the drug will constitute from about 0.1 % to about 50 % by weight of the composition, with the balance being the erodible matrix.
- The unit dosage forms of the invention can be prepared by conventional procedures such as compression molding, tableting, extrusion, and injection molding. It is preferred that the dosage forms of the invention be non-porous in order that the erosion will proceed from the surface of the dosage form. Such non-porous dosage forms are best prepared by solidification of a molten form of the composition containing all ingredients of the composition, and injection molding is especially useful for that purpose. Indeed, the dosage forms of the invention are especially adapted to production by injection molding because the erodible matrix composition of the invention has a relatively low melting temperature, and hence the injection molding can be carried out at a temperature which is not detrimental to the drug contained in the dosage form.
- The preferred dosage forms of the invention have a cylindrical shape with a diameter of about 3 mm to about 8 mm, and preferably about 5 mm. The length of the cylindrical dosage form is typically about 5 mm to about 20 mm, and is preferably about 10 mm. The preferred dosage forms may be coated on their peripheral cylindrical surfaces with a liquid-impervious non-self-supporting coating as discussed above.
- The sustained release compositions of this invention are prepared by the following general procedure.
- A premeasured amount of a polyethylene glycol is melted in a vessel, e. g., a kettle provided with a steam jacket or a heating mantle and equipped with a stirring mechanism. A temperature of about 85°C is sufficient to melt any of the polyethylene glycols. The premeasured amount of the insoluble amphiphile is then added either as a molten liquid or as a solid. It is preferred to melt the insoluble amphiphile and add it slowly to the stirred molten PEG. The long chain fatty amphiphiles useful in the compositions of this invention are generally molten at the temperature of the molten PEG and can be readily mixed with the PEG. The bioactive agent, drug or the like is then added and dissolved in the molten mixture. Other ingredients, such as disintegrants (e. g., starch), molding adjuvants (e. g., polyethylene oxide), and the like are then added and the mixture is thoroughly blended. Dosage forms may then be formed directly from the molten mixture by the procedures outlined above.
- The invention will now be further elucidated by the following examples which are included by way of illustration only.
- In the examples all percentages and parts are weight unless otherwise specified.
- This example illustrates the preparation of dosage forms of the invention containing polyethylene glycols of various molecular weights.
- A series of compositions were prepared having the following compositions:
A. PEG-1000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % B. PEG-4000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % C. PEG-8000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % D. PEG-20,000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % - Cylindrical dosage forms were molded from the compositions A - D by pouring the molten compositions into open-ended plastic molds made of polyethylene having a diameter of about 6 mm and allowing the melt to cool to room temperature. The solidified composition was then extruded from the molds and cut into lengths to prepare cylindrical dosage forms. In this way dosage forms having a diameter of about 6 mm and a length of about 14 mm and weighing about 0.44 g each were prepared.
- The sustained release properties of the dosage forms were then tested by the following procedure:
Simulated intestinal fluid (SIF) was prepared by the following procedure: - 1) 6.8 g of monobasic potassium phosphate were dissolved in 250 ml of water.
- 2) 190 ml of 0.2 N NaOH was added with stirring.
- 3) 400 ml of water and 10 ml of pancreatin were added.
- 4) The pH of the solution was adjusted with 0.2 N NaOH to 7.5 ± 0.1.
- 5) The solution was diluted with water to 1000 ml.
- Each of the cylindrical dosage forms was placed in 80 ml of SIF at 37 °C and subjected to gentle agitation. The amount of drug released was monitored by measuring the optical density of the aqueous medium at an absorption peak of indomethacin at intervals using an ultraviolet spectrophotometer. Each of the dosage forms was found to release the drug gradually over a period of several hours.
- Cylindrical dosage forms of the same size and shape as above were prepared from each of the compositions A - D, but these cylinders were coated on their cylindrical surfaces with myristic acid by dipping the cylinders in molten myristic acid, withdrawing the cylinders and allowing the myristic acid coating to cool and harden, and then scraping the coating from the ends of the cylinders. These dosage forms were tested in SIF by the same procedure as the uncoated dosage forms. They also were found to release the drug over a period of several hours with the drug release occurring at an approximately constant rate.
- This example illustrates variation of the fatty acid erosion rate modifier.
- Several dosage forms were prepared by the procedure of Example 1 having the following compositions:
A. PEG-8000 37.5 % Myristic acid 15 % Starch 22.5 % Indomethacin 25 % B. PEG-8000 37.5 % Palmitic acid 15 % Starch 22.5 % Indomethacin 25 % C. PEG-8000 37.5 % Stearic acid 15 % Starch 22.5 % Indomethacin 25 % - The dosage forms were tested by the procedure of Example 1 and were found to release the drug over a period of several hours at a relatively constant rate.
- This example illustrates another composition of the invention incorporating additional ingredients.
- A sustained release composition was prepared by the general procedure disclosed above having the following composition:
PEG-8000 27 % Palmitic acid 13 % PEG 400 monostearate 10 % PEO (MW 5 x 10⁶) 0.1 % Cornstarch 49.8 % Clonidine HCl 0.1 % - The molten mixture was poured onto a surface and allowed to cool and solidify. The solid material was then granulated and fed into an injection molding machine to form dosage forms according to the invention.
- This example illustrates preparation of PEG esters.
- PEG-8000 was melted in a vessel equipped with a stirrer and heated to 100°C. An amount of myristyl chloride equivalent to one half of the terminal hydroxyl groups of the PEG was melted and added dropwise to the molten PEG with continuous stirring. Chloroform was added to the mixture and the solution was filtered through filter paper (Whatman No. 4) and allowed to stand overnight to evaporate the solvent. The remaining solvent was evaporated the next day by heating at 60°C. The material so obtained was a hard waxy solid having a melting point of about 60°C.
- This example illustrates the preparation of dosage forms of the invention using various drugs.
- Sustained release compositions were prepared by the general procedure disclosed above having the following compositions:
A. PEG (MW 3,350) 37 % Stearyl alcohol 15 % Theophylline 50 % B. PEG 8000 30 % Myristic acid 20 % PEG 400 monostearate 10 % PEO (MW 5 x 10⁶) 0.1 % Corn starch 24.9 % Dipyridamole 15 % C. PEG-8000 2.8 g Myristic acid 1.2 g Starch 1.8 g Hydrochlorothiazide 50 mg D. PEG-8000 1.5 g Myristic acid 0.6 g Starch 0.9 g Furosemide 1.0 g E. PEG-8000 5 % Myristic acid 10 % Starch 15 % Flubiprofen 70 % F. PEG-1000 0.7 g PEG-8000 0.7 g PEG-20000 0.7 g Myristic acid 1.0 g Palmitic acid 1.0 g Stearic acid 1.0 g Starch 0.9 g KCl 6.0 g G. PEG-8000 50 % Glyceryl monostearate 5 % Starch 20 % Dipyridamole 25 % - This example illustrates a dosage form of this invention incorporating a pesticide.
- A composition of the invention was prepared by the procedure of Example 1 having the following composition:
PEG-8000 37.5 % Myristic acid 15.0 % Starch 22.5 % Carbofuran 25.0 % - Cylindrical dosage forms (uncoated) were prepared by the procedure of Example 1. These dosage forms were found to erode over a period of about one day in an aqueous environment.
- This example illustrates the preparation of a coated dosage form of the invention.
- A composition was prepared by the procedure of Example 1 having the following composition:
PEG-3350 27 % Myristic acid 13 % PEG-400 distearate 2 % Potato starch 13 % Quinidine · 2 H₂SO₄ 45 % - After mixing the molten composition was poured onto a surface and allowed to cool and harden. The hardened composition was then granulated and introduced into an extrusion apparatus. A cylindrical stream was extruded from the apparatus and coextruded therewith, so as to form a continuous coating over the extruded cylinder, was a liquid impervious coating having the following composition:
Cetyl alcohol 99 % Diethyl phthalate 1 % - The extruded cylinder was then cut into dosage forms having a length of about 10 mm and dosage forms were tested as in Example 1 and found to release the drug over a period of time.
Claims (26)
- A composition erodible by an aqeous liquid containing a polyethylene glycol and an erosion rate modifier, comprising:- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqeous liquid, and 0.1 to 10% by weight of a polyethylene glycol having a molecular weight from about 200 to about 10,000 and having at one or both ends OH groups esterified with a C₁₂ - C₂₀ aliphatic fatty acid which increases the compatibility of the polyethylene glycol and the erosion rate modifier;under the proviso that the total amount of the compounds equals 100% by weight.
- A composition erodible by an aqeous liquid containing a polyethylene glycol and an erosion rate modifier, comprising:- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqeous liquid; and- 5 to 60% by weight of starch as a disintegrant;under the proviso that the total amount of the compounds equals 100% by weight.
- A composition erodible by an aqeous liquid containing a polyethylene glycol and an erosion rate modifier, comprising:- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqeous liquid;- 5 to 60% by weight of starch as a disintegrant; and- 0.1 to 10% by weight of a polyethylene glycol having a molecular weight from about 200 to about 10,000 and having at one or both ends OH groups esterified with a C₁₂ - C₂₀ aliphatic fatty acid which increases the compatibility of the polyethylene glycol and the erosion rate modifier;under the proviso that the total amount of the compounds equals 100% by weight.
- A composition according to any one of claims 1-3 additionally comprising a biologically active compound.
- A sustained release composition in a suitable dosage form for releasing a biologically active compound into its surrounding environment comprising said biologically active compound dispersed in a matrix containing a polyethylene glycol and an erosion rate modifier which, when contacted with an aqeous liquid, erodes progressively, said matrix comprising a mixture of:- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqeous liquid;- 5 to 60% by weight of starch as a disintegrant; and- 0.1 to 10% by weight of a polyethylene glycol having a molecular weight from about 200 to about 10,000 and having at one or both ends OH groups esterified with a C₁₂ - C₂₀ aliphatic fatty acid which increases the compatibility of the polyethylene glycol and the erosion rate modifier;under the proviso that the total amount of the compounds equals 100% by weight.
- The composition of claim 5 additionally comprising up to about 2% by weight of a molding adjuvant consisting of polyethylene oxide having a molecular weight of 100,000 to 5,000,000.
- A sustained release composition in a suitable dosage form for releasing a biologically active compound into its surrounding environment comprising a pharmaceutically active compound or non-toxic pharmaceutically acceptable salt of said pharmaceutically active compound dispersed in a matrix containing a polyethylene glycol and an erosion rate modifier which, when contacted with an aqeous liquid, erodes progressively, said matrix comprising a mixture of:- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqeous liquid;- 5 to 60% by weight of starch as a disintegrant; and- 0.1 to 10% by weight of a polyethylene glycol having a molecular weight from about 200 to about 10,000 and having at one or both ends OH groups esterified with a C₁₂ - C₂₀ aliphatic fatty acid which increases the compatibility of the polyethylene glycol and the erosion rate modifier;under the proviso that the total amount of the compounds equals 100% by weight.
- The composition of claim 7 wherein said compound is clonidine.
- The composition of claim 7 wherein said compound is dipyridamole.
- The composition of claim 7 wherein said compound is furosemide.
- The composition of claim 7 wherein said compound is indomethacin.
- The composition of claim 7 wherein said compound is scopolamine.
- The composition of claim 7 wherein said compound is a bronchodilator.
- The composition of claim 13 wherein said bronchodilator is theophylline.
- A sustained release composition in a suitable dosage form for releasing an ecologically active compound into its surrounding environment comprising said ecologically active compound dispersed in a matrix containing a polyethylene glycol and an erosion rate modifier which, when contacted with an aqeous liquid, erodes progressively, said matrix comprising a mixture of:- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;- 95 to 5% by weight of an erosion rate modifier which is amphiphilic compound insoluble in said aqeous liquid;- 5 to 60% by weight of starch as a disintegrant, and- 0.1 to 10% by weight of a polyethylene glycol having a molecular weight from about 200 to about 10,000 and having at one or both ends OH groups esterified with a C₁₂ - C₂₀ aliphatic fatty acid which increases the compatibility of the polyethylene glycol and the erosion rate modifier;under the proviso that the total amount of the compounds equals 100% by weight.
- The composition of claim 15 wherein said ecologically active compound is a fertilizer.
- The composition of claim 15 wherein said ecologically active compound is a pesticide.
- The composition of claim 15 wherein said ecologically active compound is an insecticide.
- The composition of claim 15 wherein said ecologically active compound is a herbicide.
- The dosage form of claim 5-19 wherein said dosage form has the shape of a cylinder having a diameter from 3 to 8 mm and a length from 5 to 20 mm.
- The dosage form of claim 20 additionally comprising at least a partial coating of a liquid impermeable non-self-supporting coating.
- The dosage form of claim 21 wherein said coating comprises a solid C₁₂ - C₂₀ fatty acid.
- The dosage form of claim 22 wherein said coating comprises myristic acid and/or palmitic acid.
- A method of preparing a dosage form for releasing a biologically active compound into an aqeous liquid environment using a polyethylene glycol and an erosion rate modifier comprising mixing said biologically active compound with a molten composition comprising a mixture of:- 5 to 95% by weight of a polyethylene glycol having a molecular weight of from 1,000 to 20,000;- 95 to 5% by weight of an erosion rate modifier which is an amphiphilic compound insoluble in said aqeous liquid;- 5 to 60% by weight of starch as a disintegrant; and- 0.1 to 10% by weight of a polyethylene glycol having a molecular weight from about 200 to about 10,000 and having at one or both ends OH groups esterified with a C₁₂ - C₂₀ aliphatic fatty acid which increases the compatibility of the polyethylene glycol and the erosion rate modifier;under the proviso that the total amount of the compounds equals 100% by weight.
- The method of claim 24 additionally comprising up to about 2% by weight of a molding adjuvant consisting of polyethylene oxide having a molecular weight of 100,000 to 5,000,000.
- The composition of anyone of the preceding claims, characterized in that the erosion rate modifiers include C₁₂ - C₂₀ fatty acids, such as lauric acid, myristic acid, palmitic acid, stearic acid and arachidic acid; C₁₂ - C₂₀ alcohols, such as lauryl alcohol, myristyl alcohol, palmityl alcohol, stearyl alcohol and arachidyl alcohol, amphiphilic esters of fatty acids with glycerol, particularly monoesters of C₁₂ - C₂₀ fatty acids such as glyceryl monopalmitate, C₁₂ - C₂₀ amines such as lauryl amine, myristyl amine, palmityl amine, stearyl amine and arachidyl amine, and amides of C₁₂ - C₂₀ fatty acids.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US633604 | 1984-07-23 | ||
US06/633,604 US4629621A (en) | 1984-07-23 | 1984-07-23 | Erodible matrix for sustained release bioactive composition |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0190255A1 EP0190255A1 (en) | 1986-08-13 |
EP0190255A4 EP0190255A4 (en) | 1987-10-20 |
EP0190255B1 true EP0190255B1 (en) | 1992-11-11 |
Family
ID=24540333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP85903908A Expired - Lifetime EP0190255B1 (en) | 1984-07-23 | 1985-07-17 | Erodible matrix for sustained release bioactive composition |
Country Status (7)
Country | Link |
---|---|
US (4) | US4629621A (en) |
EP (1) | EP0190255B1 (en) |
JP (1) | JPS61502759A (en) |
AU (1) | AU573149B2 (en) |
CA (1) | CA1246448A (en) |
DE (1) | DE3586823T2 (en) |
WO (1) | WO1986000802A1 (en) |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US4780236A (en) * | 1986-06-20 | 1988-10-25 | Kiwi Brands, Inc. | Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride |
US4804400A (en) * | 1986-09-12 | 1989-02-14 | Ciba-Geigy Corporation | N-phenyl-maleimides and herbicidal and plant growth regulating methods of use thereof |
US5310572A (en) * | 1987-02-03 | 1994-05-10 | Dow Corning Corporation | Process for forming a coated active agent-containing article |
US5085861A (en) * | 1987-03-12 | 1992-02-04 | The Beth Israel Hospital Association | Bioerodable implant composition comprising crosslinked biodegradable polyesters |
US4843112A (en) * | 1987-03-12 | 1989-06-27 | The Beth Israel Hospital Association | Bioerodable implant composition |
DE3879031T2 (en) * | 1987-08-08 | 1993-06-24 | Akzo Nv | CONCEPTUAL IMPLANT. |
US5137669A (en) * | 1988-03-02 | 1992-08-11 | Endocon, Inc. | Manufacture of partially fused peptide pellet |
US5034267A (en) * | 1988-03-04 | 1991-07-23 | The Dow Chemical Company | Carbonaceous fiber or fiber assembly with inorganic coating |
US4944999A (en) * | 1988-03-04 | 1990-07-31 | The Dow Chemical Company | Carbonaceous fiber or fiber assembly with inorganic coating |
US5028477A (en) * | 1988-03-04 | 1991-07-02 | The Dow Chemical Company | Carbonaceous fiber or fiber assembly with inorganic coating |
US4978571A (en) * | 1988-03-04 | 1990-12-18 | The Dow Chemical Company | Carbonaceous fiber or fiber assembly with inorganic coating |
EP0406315B1 (en) * | 1988-03-24 | 1992-11-11 | Bukh Meditec A/S | Controlled release composition |
US5135752A (en) * | 1988-10-14 | 1992-08-04 | Zetachron, Inc. | Buccal dosage form |
US5139790A (en) * | 1988-10-14 | 1992-08-18 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
US5004601A (en) * | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
SE8803935L (en) * | 1988-10-31 | 1990-05-01 | Kabivitrum Ab | LAEKEMEDELSKOMPOSITION |
JP2893191B2 (en) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | Controlled release matrix agent |
DE3933000A1 (en) * | 1989-10-03 | 1991-04-11 | Int Pharma Agentur | Erosion-controlled active agent release system |
US4990336A (en) * | 1989-02-08 | 1991-02-05 | Biosearch, Inc. | Sustained release dosage form |
DK469989D0 (en) * | 1989-09-22 | 1989-09-22 | Bukh Meditec | PHARMACEUTICAL PREPARATION |
US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
CA2031313C (en) * | 1990-12-03 | 2000-09-05 | Barry R. Pittendrigh | Method of mosquito control |
US5403593A (en) * | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
US5302393A (en) * | 1991-07-11 | 1994-04-12 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Method for inhibiting biological degradation of implantation polymeric material, inhibitor thereof and implantation polymeric material containing the inhibitor |
WO1993001800A1 (en) * | 1991-07-24 | 1993-02-04 | Thomas Sai Ying Ko | Therapeutic compositions and methods |
US5335449A (en) * | 1991-08-15 | 1994-08-09 | Net/Tech International, Inc. | Delivery system for an agriculturally active chemical |
US5526607A (en) * | 1991-08-15 | 1996-06-18 | Net/Tech International | Water dispersible delivery system for an agriculturally active chemical |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
RU2121830C1 (en) * | 1992-09-18 | 1998-11-20 | Яманоути Фармасьютикал Ко., ЛТД | Hydrogel preparation exhibiting the sustained drug release |
US20080075781A1 (en) * | 1992-11-25 | 2008-03-27 | Purdue Pharma Lp | Controlled release oxycodone compositions |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US20070275062A1 (en) * | 1993-06-18 | 2007-11-29 | Benjamin Oshlack | Controlled release oxycodone compositions |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
US5430021A (en) * | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
US5484608A (en) * | 1994-03-28 | 1996-01-16 | Pharmavene, Inc. | Sustained-release drug delivery system |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
US20040191314A1 (en) * | 1994-04-28 | 2004-09-30 | Frank Jao | Antiepileptic dosage form and process for protecting antiepileptic drug |
US5599583A (en) * | 1994-05-27 | 1997-02-04 | Micro Flo Company | Encapsulation with water soluble polymer |
GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
GB9519363D0 (en) * | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
EP1014941B2 (en) | 1996-06-26 | 2017-05-17 | The Board Of Regents, The University Of Texas System | Hot-melt extrudable pharmaceutical formulation |
US5868991A (en) * | 1996-07-26 | 1999-02-09 | Kimberly-Clark Worldwide, Inc. | Method for low temperature injection molding of hydrodisintegratable compositions |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
DE19916383A1 (en) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmaceutical composition with an extrusion |
DE19918325A1 (en) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US7169889B1 (en) | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
AR024966A1 (en) | 1999-07-30 | 2002-10-30 | Smithkline Beecham Plc | PHARMACEUTICAL FORMULATION |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
CN102716101A (en) | 1999-10-29 | 2012-10-10 | 欧罗赛铁克股份有限公司 | Controlled release hydrocodone formulations |
US6503528B1 (en) * | 1999-11-19 | 2003-01-07 | Abbott Laboratories | Polymeric compositions and a method of making the same |
US6475505B1 (en) * | 1999-12-20 | 2002-11-05 | Ciba Specialty Chemicals Corporation | Biocide-polyester concentrates and biocidal compositions prepared therefrom |
US6544553B1 (en) * | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
US6419954B1 (en) * | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
DE10026698A1 (en) * | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
EP2283829A1 (en) | 2000-10-30 | 2011-02-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US6756051B1 (en) | 2000-11-15 | 2004-06-29 | Li-Lan H. Chen | Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same |
JP2004514702A (en) | 2000-11-29 | 2004-05-20 | オキュレックス ファーマシューティカルズ, インコーポレイテッド | Intraocular implant for preventing transplant rejection in the eye |
US7842308B2 (en) | 2001-01-30 | 2010-11-30 | Smithkline Beecham Limited | Pharmaceutical formulation |
US20050175687A1 (en) * | 2001-01-30 | 2005-08-11 | Mcallister Stephen M. | Pharmaceutical formulations |
GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
US7883721B2 (en) | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
CN1491105A (en) * | 2001-02-13 | 2004-04-21 | Novel modified released formulation | |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
UA81224C2 (en) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
CA2446705C (en) * | 2001-05-03 | 2012-03-06 | David F. Woodward | Compositions of quinoxaline-based therapeutic agents and fatty acids having enhanced pharmacokinetic characteristics |
US20020198210A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Alpha-2-adrenergic agonist/fatty acid compositions |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US6913903B2 (en) | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
KR100446818B1 (en) * | 2001-11-06 | 2004-09-01 | 김재윤 | Sustained release pellet of isosorbide dinitrate |
EP2522319A3 (en) * | 2002-03-11 | 2013-09-25 | Novartis AG | Implantable drug delivery system |
AU2003236521A1 (en) * | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US20050100608A1 (en) * | 2003-02-21 | 2005-05-12 | Watson Pharmaceuticals, Inc. | Testosterone oral dosage formulations and associated methods |
US7442387B2 (en) * | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
US20050042289A1 (en) * | 2003-04-29 | 2005-02-24 | Yamanouchi Pharma Technologies, Inc. | Tablets and methods for modified release of hydrophylic and other active agents |
US7135436B2 (en) * | 2003-05-05 | 2006-11-14 | J.F. Daley International, Ltd. | Solid algicide, preparation and usage in recirculating water |
TW200526274A (en) | 2003-07-21 | 2005-08-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE10361596A1 (en) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
NZ545202A (en) * | 2003-08-06 | 2010-03-26 | Gruenenthal Chemie | Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide |
DE102004020220A1 (en) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
JP2007521231A (en) * | 2003-08-08 | 2007-08-02 | バイオヴェイル ラボラトリーズ インコーポレイテッド | Controlled release tablets of bupropion hydrochloride |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
TW201240679A (en) * | 2004-03-12 | 2012-10-16 | Capsugel Belgium Nv | Pharmaceutical formulations |
EP1591107A1 (en) * | 2004-04-28 | 2005-11-02 | Pfizer GmbH Arzneimittelwerk Gödecke | Process for the selective increase of a release rate of an active material from a pharmaceutical composition |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
DE102004032103A1 (en) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
RU2393168C2 (en) * | 2004-07-19 | 2010-06-27 | Биокон Лимитед | Insulin-oligomer conjugates, preparations and use thereof |
DK1836665T3 (en) | 2004-11-19 | 2013-04-15 | Glaxosmithkline Llc | PROCEDURE FOR SPECIAL CUSTOMIZED DELIVERY OF VARIABLE DOSAGE MEDICINE COMBINATION PRODUCTS FOR INDIVIDUALIZATION OF THERAPIES |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
JP5095615B2 (en) | 2005-06-27 | 2012-12-12 | バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ | Modified release of bupropion salt |
US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US8802128B2 (en) * | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
WO2008011596A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
DE102007011485A1 (en) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
CN101827571A (en) | 2007-10-15 | 2010-09-08 | 葛兰素集团有限公司 | Linkers for multipart dosage forms for release of one or more pharmaceutical compositions, and the resulting dosage forms |
WO2009050193A1 (en) * | 2007-10-15 | 2009-04-23 | Glaxo Group Limited | Method and apparatus for manufacturing filled linkers |
JP2011500627A (en) * | 2007-10-15 | 2011-01-06 | グラクソ グループ リミテッド | Paneled capsule shell for release of pharmaceutical composition |
MX2010003979A (en) * | 2007-10-16 | 2010-06-02 | Biocon Ltd | An orally administerable solid pharmaceutical composition and a process thereof. |
JP2011503048A (en) | 2007-11-08 | 2011-01-27 | グラクソ グループ リミテッド | Pharmaceutical formulation |
KR101616246B1 (en) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | Pharmaceutical dosage form |
US20090246276A1 (en) | 2008-01-28 | 2009-10-01 | Graham Jackson | Pharmaceutical Compositions |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
MX2010012039A (en) | 2008-05-09 | 2010-11-30 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step. |
TW201010745A (en) * | 2008-06-13 | 2010-03-16 | Glaxo Group Ltd | Pharmaceutical formulations |
WO2010014952A2 (en) * | 2008-07-31 | 2010-02-04 | Clarke Mosquito Control Products, Inc. | Extended release tablet and method for making and using same |
MX2012000317A (en) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form. |
RU2015138422A (en) | 2009-07-22 | 2018-12-25 | Грюненталь Гмбх | STABLE DURING OXIDATION, STRONG-BREAKED DOSAGE FORM |
WO2011040956A1 (en) * | 2009-09-29 | 2011-04-07 | Michael Burnet | Novel pesticide formulations |
WO2011095314A2 (en) | 2010-02-03 | 2011-08-11 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
ES2487244T3 (en) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Handling resistant dosage form comprising an anionic polymer |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US9233076B2 (en) | 2010-12-13 | 2016-01-12 | Purdue Pharma L.P. | Controlled release dosage forms |
CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
AU2012292418B2 (en) | 2011-07-29 | 2017-02-16 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
MX356421B (en) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer. |
CN104394851B (en) | 2012-04-18 | 2017-12-01 | 格吕伦塔尔有限公司 | Anti-distort and anti-agent amount are come down in torrents pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
AR096438A1 (en) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | DOSAGE FORM RESISTANT TO INDEBITED USE WITH BIMODAL RELEASE PROFILE, PROCESS |
BR112016000194A8 (en) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | tamper-resistant dosage form containing ethylene vinyl acetate polymer |
CN105934241B (en) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | Preparation of powdered pharmaceutical composition by cryogenic grinding |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2017516789A (en) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Multiparticulates protected against ethanol overdose |
US10653622B1 (en) | 2015-04-13 | 2020-05-19 | Pharmacoustics Technologies LLC | Individualized solid dosage products and a system and method for the globally integrated pharmaceutical manufacturing and its monitoring thereof |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
EP3703724A1 (en) | 2017-11-02 | 2020-09-09 | NatureCeuticals Sdn. Bhd. | Extract of orthosiphon stamineus, formulations, and uses thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE287292C (en) * | ||||
DE557608C (en) * | 1927-02-12 | 1932-08-25 | Pharmaceutische Werke Norgine | Process for the production of small intestinal pills and lozenges |
US2517513A (en) * | 1943-02-27 | 1950-08-01 | Vaernet Carl | Pharmaceutical preparation for implantation |
BE623704A (en) * | 1961-10-20 | |||
DE1249823B (en) * | 1964-01-15 | 1967-09-14 | ||
US3374146A (en) * | 1966-04-18 | 1968-03-19 | American Cyanamid Co | Sustained release encapsulation |
GB1209093A (en) * | 1968-07-16 | 1970-10-14 | Delandale Lab Ltd | Pharmaceutical preparation |
US3634584A (en) * | 1969-02-13 | 1972-01-11 | American Home Prod | Sustained action dosage form |
US3947573A (en) * | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
JPS50126838A (en) * | 1974-01-17 | 1975-10-06 | ||
FI63335B (en) * | 1979-02-02 | 1983-02-28 | Orion Yhtymae Oy | FARING REFERENCE FOR A TABLETTER WITH A LIGHT LIGHT OF AN EFFECTIVE |
US4333919A (en) * | 1979-09-12 | 1982-06-08 | Eli Lilly And Company | Growth promotant controlled release formulations and method of treatment |
US4346709A (en) * | 1980-11-10 | 1982-08-31 | Alza Corporation | Drug delivery devices comprising erodible polymer and erosion rate modifier |
DE3217071A1 (en) * | 1982-05-06 | 1983-11-10 | Rüdiger Dr. 6365 Rosbach Gröning | Pharmaceutical composition for oral administration with improved bioavailability of the active substances |
IE54171B1 (en) * | 1982-06-22 | 1989-07-05 | Univ Glasgow | Device for introducing nutrients and/or therapeutic materials into ruminant animals |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
-
1984
- 1984-07-23 US US06/633,604 patent/US4629621A/en not_active Expired - Lifetime
-
1985
- 1985-07-12 CA CA000486711A patent/CA1246448A/en not_active Expired
- 1985-07-17 EP EP85903908A patent/EP0190255B1/en not_active Expired - Lifetime
- 1985-07-17 WO PCT/US1985/001349 patent/WO1986000802A1/en active IP Right Grant
- 1985-07-17 DE DE8585903908T patent/DE3586823T2/en not_active Expired - Fee Related
- 1985-07-17 AU AU46388/85A patent/AU573149B2/en not_active Ceased
- 1985-07-17 JP JP60503436A patent/JPS61502759A/en active Pending
-
1986
- 1986-10-14 US US06/918,273 patent/US4806337A/en not_active Expired - Lifetime
- 1986-10-14 US US06/918,294 patent/US4744976A/en not_active Expired - Lifetime
- 1986-10-14 US US06/918,274 patent/US4774074A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE3586823T2 (en) | 1993-05-13 |
US4629621A (en) | 1986-12-16 |
EP0190255A1 (en) | 1986-08-13 |
US4806337A (en) | 1989-02-21 |
US4774074A (en) | 1988-09-27 |
WO1986000802A1 (en) | 1986-02-13 |
EP0190255A4 (en) | 1987-10-20 |
US4744976A (en) | 1988-05-17 |
CA1246448A (en) | 1988-12-13 |
JPS61502759A (en) | 1986-11-27 |
AU573149B2 (en) | 1988-05-26 |
DE3586823D1 (en) | 1992-12-17 |
AU4638885A (en) | 1986-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0190255B1 (en) | Erodible matrix for sustained release bioactive composition | |
US5082655A (en) | Pharmaceutical composition for drugs subject to supercooling | |
JP2559785B2 (en) | Delayed-release active ingredient drug and method for producing the same | |
EP0632720B1 (en) | Hydroxyethylcellulose-based sustained-release oral drug dosage froms | |
US8084053B2 (en) | Dry mouldable drug formulation | |
CA1295247C (en) | Sustained release capsule | |
JP4989217B2 (en) | Matrix composition for controlled delivery of drug substance | |
EP0531611B1 (en) | Controlled release matrix for pharmaceuticals | |
US3108046A (en) | Method of preparing high dosage sustained release tablet and product of this method | |
US3146167A (en) | Method of preparing sustained release pellets and products thereof | |
JPH05500668A (en) | controlled release composition | |
DE4201179A1 (en) | Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc. | |
FI96095C (en) | A method of preparing a sustained release medicament | |
DE3626362A1 (en) | DISCHARGE DEVICE FOR RELEASING AN ACTIVE SUBSTANCE TO RETURN | |
IE880855L (en) | Slow-release pharmaceutical agent | |
WO2002011701A1 (en) | A controlled release pharmaceutical composition | |
WO1996031197A1 (en) | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release | |
KR20070119700A (en) | Formulations containing fenofibrate and surfactant mixture | |
SK76994A3 (en) | Dosing form with successive recease of drug in dispersion form and method of its production | |
AU2002228119B2 (en) | Thermoformable solid pharmaceutical composition for controlled release of ivabradine | |
DE3400106A1 (en) | Pharmaceutical compositions with controlled release of medicinal substance | |
JP3247693B2 (en) | Sustained release formulation | |
JP3296579B2 (en) | Compounds with controlled component release | |
JPH08245422A (en) | Thermoplastic coating and binder for medical form and peroral or percutaneous medical form containing this | |
FI93425C (en) | Process for the preparation of orally stabilized, active substance retarded and controlled release, drug preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19860326 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB LI NL |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19871020 |
|
17Q | First examination report despatched |
Effective date: 19890502 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ZETACHRON, INC. |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB LI NL |
|
REF | Corresponds to: |
Ref document number: 3586823 Country of ref document: DE Date of ref document: 19921217 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19970115 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19970117 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19970130 Year of fee payment: 12 Ref country code: CH Payment date: 19970130 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19970131 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19970217 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970717 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970731 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970731 |
|
BERE | Be: lapsed |
Owner name: ZETACHRON INC. Effective date: 19970731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980201 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19970717 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980331 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19980201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980401 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19960731 |